Last updated: November 9, 2026
Astellas Pharma Inc. sued Sandoz Inc. in the U.S. District Court for the District of Delaware after Sandoz filed an abbreviated new drug application (ANDA) for generic Myrbetri, the extended-release mirabegron product. The case involved Orange Book-listed patents covering mirabegron extended-release tablets and was resolved through a confidential settlement rather than a trial or merits judgment. The docket is closed.
What drug and patents were involved in Astellas v. Sandoz?
The dispute concerned Myrbetri, whose active ingredient is mirabegron. Astellas markets Myrbetri for overactive bladder, including urinary urgency, increased urinary frequency and urge urinary incontinence.
Sandoz's ANDA sought approval for a generic version of Myrbetri extended-release tablets. Astellas alleged that Sandoz's ANDA filing infringed patents listed for Myrbetri under the Hatch-Waxman Act.
Core case information
| Item |
Detail |
| Case |
Astellas Pharma Inc. v. Sandoz Inc. |
| Court |
U.S. District Court for the District of Delaware |
| Civil action |
No. 1:20-cv-01589 |
| Judge |
Richard G. Andrews |
| Plaintiff |
Astellas Pharma Inc. |
| Defendant |
Sandoz Inc. |
| Product |
Myrbetri, mirabegron extended-release tablets |
| Regulatory pathway |
ANDA |
| Filing year |
2020 |
| Litigation type |
Hatch-Waxman patent infringement action |
| Outcome |
Settlement and dismissal |
| Trial outcome |
No merits trial or infringement judgment |
| Settlement terms |
Confidential |
The asserted patent portfolio centered on Astellas patents directed to pharmaceutical compositions containing mirabegron and extended-release dosage forms. Publicly available case and Orange Book materials identify, among other patents associated with Myrbetri, U.S. Patent Nos. 8,835,474 and 9,907,794. The precise claim scope and patent list must be read from the complaint, infringement contentions and Orange Book records for the relevant filing date. (U.S. Food and Drug Administration [FDA], 2024a; U.S. District Court for the District of Delaware, 2020).
What patent claims did Astellas assert against Sandoz?
Astellas's case was principally a formulation and dosage-form dispute rather than a simple dispute over the chemical identity of mirabegron.
The relevant patent claims generally addressed:
- Mirabegron-containing pharmaceutical compositions.
- Extended-release oral dosage forms.
- Tablet compositions designed to deliver mirabegron over a controlled period.
- Excipients and formulation characteristics used to achieve the product's release profile.
- Commercial formulations corresponding to Myrbetri tablets.
The practical significance was substantial. A generic manufacturer may be able to synthesize mirabegron but still face infringement exposure if its ANDA product uses a protected extended-release formulation. Formulation patents can therefore delay generic entry even when an earlier compound patent has expired or is vulnerable to invalidity challenges.
Formulation protection versus compound protection
Myrbetri's patent estate illustrates the distinction between:
| Protection category |
Commercial relevance |
| Compound patents |
Protect mirabegron itself and generally provide the broadest exclusivity |
| Composition patents |
Protect the drug combined with specified formulation components |
| Extended-release patents |
Protect the delivery profile and tablet architecture |
| Method-of-use patents |
Protect use of mirabegron for specified patient populations or conditions |
| Manufacturing patents |
Can restrict production routes or intermediate chemistry |
The Sandoz case was commercially important because formulation claims can block an ANDA product even when the generic applicant avoids copying a particular brand manufacturing process.
What was the procedural history of the Sandoz litigation?
Astellas filed the action after receiving Sandoz's ANDA-related Paragraph IV notice. Under the Hatch-Waxman framework, a Paragraph IV certification alleges that an Orange Book-listed patent is invalid, unenforceable or will not be infringed by the proposed generic product.
Litigation timeline
| Date |
Event |
| 2020 |
Sandoz submitted an ANDA for generic mirabegron extended-release tablets and provided Paragraph IV notice |
| 2020 |
Astellas filed the Delaware infringement action |
| 2020-2021 |
Pleadings, claim-construction preparation and discovery proceeded |
| 2021-2022 |
The parties resolved the dispute through a confidential settlement |
| After settlement |
The action was dismissed and closed without a merits decision |
The 30-month stay triggered by the patent litigation would have limited FDA approval of Sandoz's ANDA during the statutory stay period, subject to the usual exceptions. Because the case settled, the docket did not produce a judicial determination that the asserted patents were valid, enforceable or infringed.
Was Sandoz's Paragraph IV challenge successful?
No merits outcome was entered. Sandoz did not obtain a court judgment invalidating the asserted patents, and Astellas did not obtain a trial judgment confirming infringement.
The dismissal therefore should not be characterized as either a patent victory or a patent defeat. The commercial result depended on the private settlement terms, which were not publicly disclosed in the docket.
A settlement can provide a generic applicant with a negotiated launch date, a license, or other commercialization rights without resolving the legal merits. It can also preserve the brand's patent position against other generic applicants because the settlement does not create binding precedent on claim construction or validity.
What was the settlement and when could Sandoz launch generic Myrbetri?
The settlement terms were confidential. The public case record does not establish a definitive Sandoz launch date, royalty structure, authorized-generic arrangement or license scope.
The case therefore does not support a confirmed statement that Sandoz could launch on a particular date. A launch date disclosed in another generic company's settlement should not be attributed to Sandoz without a Sandoz-specific agreement or regulatory filing.
Generic-entry scenarios
| Scenario |
Effect on Sandoz |
| Settlement license before patent expiry |
Sandoz may launch on the negotiated date, subject to FDA approval |
| No commercial launch provision |
Sandoz remains constrained by the patent rights and regulatory status |
| Authorized generic arrangement |
Astellas could control timing and supply economics |
| Successful invalidity or noninfringement decision |
Sandoz could launch before the scheduled patent expiry |
| Patent expiration without earlier launch |
Entry could occur after the surviving patent barriers lapse |
The confidential settlement makes the first scenario commercially plausible but not publicly quantifiable from the docket.
What is the Orange Book status of Myrbetri?
Myrbetri is an FDA-approved prescription drug, and its listed patents have been central to generic ANDA litigation.
The FDA approved Myrbetri in 2012 for overactive bladder. The product later received additional approval for certain pediatric neurogenic detrusor overactivity indications. FDA approval does not itself determine the enforceability of every Orange Book patent. The Orange Book identifies patents submitted by the NDA holder and associated with the approved drug, while courts decide infringement, validity and enforceability disputes. (FDA, 2012; FDA, 2024a).
Regulatory and exclusivity profile
| Issue |
Analysis |
| FDA approval |
Myrbetri was approved in 2012 |
| Active ingredient |
Mirabegron |
| Drug type |
Small-molecule oral extended-release product |
| NCE exclusivity |
Expired after the statutory five-year period |
| Pediatric exclusivity |
May extend listed exclusivity periods where applicable |
| Biosimilar pathway |
Not applicable |
| Generic pathway |
ANDA under Hatch-Waxman |
| Orange Book relevance |
High, because listed patents triggered Paragraph IV litigation |
Myrbetri is not a biologic. Biosimilar litigation concepts do not apply. The principal competitive threat is conventional generic mirabegron, particularly products that replicate the extended-release profile.
When does Myrbetri lose patent exclusivity?
Myrbetri does not have a single legally operative exclusivity date for all commercial purposes. Different patents may expire on different dates, and patent term adjustment, patent-term extension, pediatric exclusivity and later-issued continuation patents can affect the effective barrier.
The key commercial distinction is between:
- FDA regulatory exclusivity, which is time-limited and separate from patent rights; and
- Patent exclusivity, which depends on the validity and scope of each listed patent.
Public Orange Book records should be used to verify the current expiration date for each Myrbetri patent. The case itself did not establish an earlier expiration date because the parties settled before judgment. (FDA, 2024a).
How strong is the Astellas Myrbetri patent estate?
The estate was commercially meaningful but litigation strength cannot be measured from the Sandoz docket alone.
Strengths
- The patents were listed in the Orange Book.
- The claims targeted the commercial extended-release product.
- Formulation claims can be difficult to design around when the release profile is part of the approved product specification.
- A Paragraph IV challenge triggered litigation and delayed ordinary ANDA approval during the statutory stay.
- Multiple patents can create cumulative entry barriers.
Weaknesses and litigation risks
- Formulation patents generally have narrower claim scope than compound patents.
- Invalidity challenges may target written description, enablement, obviousness and claim construction.
- A generic applicant can design around specific excipients or release mechanisms.
- The absence of a merits judgment leaves the patents' litigated validity and infringement status unresolved.
- Patent-term calculations may vary by patent and regulatory event.
The settlement indicates that the parties placed value on avoiding litigation risk, but it does not prove that Sandoz's product infringed or that the asserted claims would have survived trial.
Which companies were competing with Sandoz in generic mirabegron?
Generic mirabegron litigation involved multiple ANDA applicants, reflecting the commercial value of the product and the attractiveness of the overactive-bladder market. Potential competitors included large generic manufacturers that filed ANDAs or entered related patent disputes with Astellas.
The competitive landscape has several layers:
- Sandoz and other ANDA applicants seeking direct generic entry.
- Astellas as the branded product sponsor.
- Potential authorized-generic supply arrangements.
- Other overactive-bladder therapies, including antimuscarinic products and competing beta-3 adrenergic agonists.
- Combination-product competition, including products pairing mirabegron with solifenacin.
A generic launch would place pressure on Myrbetri pricing, formulary positioning and prescription volume. The impact would depend on the number of entrants, launch timing and whether Astellas had an authorized-generic strategy.
What revenue exposure did the litigation create for Astellas?
Myrbetri was a material commercial product for Astellas. Astellas has reported global sales for the Myrbetri/Mirabegron franchise in its annual securities filings. The product's exposure was greater than the direct revenue attributable to the Sandoz case because an early Sandoz launch could affect:
- Net sales of branded Myrbetri.
- Price concessions to pharmacy benefit managers.
- Formulary placement.
- Market share in overactive bladder.
- Sales of related combination products.
- The valuation of remaining patent life.
Revenue exposure cannot be calculated solely from the civil docket. It requires the relevant Astellas reporting period, geographic scope and assumptions about generic penetration. A single generic entrant normally causes less price erosion than multiple simultaneous entrants, while an authorized generic can alter the speed and magnitude of the decline.
What is the litigation status of Astellas v. Sandoz today?
The action is closed. The parties resolved the dispute confidentially, and the court dismissed the case without a trial judgment.
The case has limited precedential value. It is useful for identifying the patents, product and regulatory pathway involved, but it does not establish:
- That Sandoz infringed the asserted claims.
- That the claims were valid.
- That the claims were enforceable.
- A public Sandoz launch date.
- The royalty or license terms.
- The existence of an authorized-generic arrangement.
Key Takeaways
- Astellas v. Sandoz, No. 1:20-cv-01589, was a Hatch-Waxman case involving generic mirabegron extended-release tablets.
- The branded product was Myrbetri, marketed by Astellas for overactive bladder.
- The dispute focused on Orange Book-listed formulation and extended-release patents, including U.S. Patent Nos. 8,835,474 and 9,907,794.
- Sandoz's Paragraph IV filing triggered federal patent litigation and the statutory regulatory stay.
- The case ended in a confidential settlement and dismissal, not a trial or merits ruling.
- The public docket does not establish Sandoz's launch date or the settlement's economic terms.
- Biosimilar risk is irrelevant because mirabegron is a small-molecule drug; generic ANDA competition is the relevant entry risk.
- The patent estate's commercial value depends on the surviving Orange Book patents, their expiration dates and any negotiated launch rights.
Frequently Asked Questions
What was Astellas Pharma Inc. v. Sandoz Inc. about?
It was a Delaware Hatch-Waxman patent case involving Sandoz's ANDA for generic Myrbetri, or mirabegron extended-release tablets.
Did Sandoz win the Myrbetri patent case?
Neither party obtained a merits judgment. The case was settled and dismissed before trial.
Is Myrbetri a biologic subject to biosimilar competition?
No. Myrbetri is a small-molecule drug. Generic mirabegron, not a biosimilar, is the relevant competitive product.
Are the Astellas-Sandoz settlement terms public?
No. The public docket does not disclose the negotiated launch date, royalty terms, license terms or supply arrangements.
Can another generic company rely on the Sandoz settlement?
No. A private settlement generally does not resolve the validity or infringement of the asserted patents for other ANDA applicants and does not establish a public launch right for unrelated companies.
References
-
Astellas Pharma Inc. v. Sandoz Inc., No. 1:20-cv-01589-RGA, U.S. District Court for the District of Delaware, docket and pleadings (2020-2022).
-
U.S. Food and Drug Administration. (2012). FDA approves new treatment for overactive bladder. Silver Spring, MD: FDA.
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. Silver Spring, MD: FDA.
-
U.S. Food and Drug Administration. (2024b). Drugs@FDA: Myrbetri application and approval history. Silver Spring, MD: FDA.
-
Astellas Pharma Inc. (2024). Annual report and securities filings. Tokyo: Astellas Pharma Inc.
